REG - AstraZeneca PLC - AstraZeneca to manufacture ADCs in Singapore

AstraZenecaAnnouncement

20/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240520:nRST0014Pa&default-theme=true

RNS Number : 0014P  AstraZeneca PLC  20 May 2024

20 May 2024

 

AstraZeneca plans $1.5 billion manufacturing facility

for antibody drug conjugates (ADCs) in Singapore

 

Operationally ready by 2029, it will be the Company's

first-ever facility to cover the full manufacturing process for ADCs

 

AstraZeneca intends to build a $1.5 billion manufacturing facility in
Singapore for antibody drug conjugates (ADCs), enhancing global supply of its
ADC portfolio. ADCs are next-generation treatments that deliver highly potent
cancer-killing agents directly to cancer cells through a targeted antibody.

 

The planned greenfield facility, supported by the Singapore Economic
Development Board (EDB), will be AstraZeneca's first end-to-end ADC production
site, fully incorporating all steps of the manufacturing process at a
commercial scale. Manufacturing of ADCs is a multi-step process that comprises
antibody production, synthesis of chemotherapy drug and linker, conjugation of
drug-linker to the antibody, and filling of the completed ADC substance.

 

Png Cheong Boon, Chairman, EDB said: "We welcome AstraZeneca's decision to
establish a manufacturing presence in Singapore for the first time. It will
also be a first for AstraZeneca - an end-to-end manufacturing facility for
novel antibody drug conjugates that enables precision therapy for cancer. This
greenfield investment is a strong show of confidence in Singapore's
biopharmaceutical manufacturing capabilities and talent, strengthens our
ecosystem in supporting the development and manufacturing of precision
medicines, and creates meaningful jobs and economic opportunities for
Singapore. We look forward to a successful partnership with AstraZeneca."

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "AstraZeneca has
built an industry-leading portfolio of cancer medicines including antibody
drug conjugates which have shown enormous potential to replace traditional
chemotherapy for patients across many settings. Singapore is one of the
world's most attractive countries for investment given its reputation for
excellence in complex manufacturing, and I am excited for AstraZeneca to
locate our $1.5 billion ADC manufacturing facility in the country."

 

AstraZeneca has a broad portfolio of in-house ADCs including six wholly owned
ADCs in the clinic and many more in preclinical development.

 

As part of AstraZeneca's commitment to driving sustainability in healthcare,
the Company will work with Singapore's government and other partners on green
solutions for the ADC facility.  This facility will be designed to emit zero
carbon from its first day of operations.

 

AstraZeneca aims to begin design and construction of the manufacturing
facility by the end of 2024, with targeted operational readiness from 2029.

 
Notes

 

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Social Media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

 

Contacts
For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXSNFLELEEA